Anson Funds Management LP Buys 993,401 Shares of NRx Pharmaceuticals, Inc. $NRXP

Key Points

• Anson Funds Management LP increased its stake in NRx Pharmaceuticals by 535.1%, acquiring 993,401 shares during the first quarter and now holds approximately 6.82% of the company.
• Several analysts have given NRx Pharmaceuticals a consensus rating of "Buy" with price targets ranging from $34.00 to $40.00, indicating positive sentiment towards the stock.
• NRx Pharmaceuticals recently reported a loss of ($0.98) earnings per share, which missed the consensus estimate, with predictions pointing towards a challenging fiscal year ahead.

Anson Funds Management LP lifted its stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) by 535.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,179,061 shares of the company's stock after purchasing an additional 993,401 shares during the quarter. Anson Funds Management LP owned 6.82% of NRx Pharmaceuticals worth $2,417,000 as of its most recent SEC filing.

Separately, Squarepoint Ops LLC bought a new position in NRx Pharmaceuticals in the 4th quarter worth about $56,000. 4.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HC Wainwright assumed coverage on NRx Pharmaceuticals in a research report on Monday. They set a "buy" rating and a $40.00 price target on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Monday. BTIG Research reiterated a "buy" rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. Finally, Wall Street Zen upgraded NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $34.50.

NRx Pharmaceuticals Stock Performance

NRx Pharmaceuticals stock opened at $2.97 on Thursday. NRx Pharmaceuticals, Inc. has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The stock has a market cap of $58.84 million, a P/E ratio of -1.33 and a beta of 1.63. The firm's fifty day moving average price is $2.81 and its 200-day moving average price is $2.55.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.67). On average, analysts predict that NRx Pharmaceuticals, Inc. will post -1.75 earnings per share for the current year.

NRx Pharmaceuticals Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.